Dagmar proposals unfeasible and hanging on a thread?
This article was originally published in Clinica
The more I think about it and the more I talk to others in the medical devices sector about European Parliament rapporteur Dagmar Roth-Behrendt’s proposals for centralised marketing authorisation by a new committee within the EMA and decentralised authorisation for some devices, the more convinced I am that her suggestions are unfeasible.
You may also be interested in...
Where are the biggest challenges for notified bodies and manufacturers now there is some experience with the MDR, and can the sector manage the new regulatory requirements successfully?
The European Commission has finally published detailed guidance on the EU IVDR’s classification rules. The IVDR’s completely new classification regime means guidance is urgently needed.
Do you know how to avoid the pitfalls when it comes to clinical evidence under the MDR? Or whether evidence gathered outside the US counts? Amie Smirthwaite of Maetrics answers these and other pivotal questions in this third and final part of an interview series with Medtech Insight.